Kidney cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 9, 2011, Pages 960-977

  Motzer, Robert J ^a   Agarwal, Neeraj ^b   Beard, Clair ^c   Bhayani, Sam ^d   Bolger, Graeme B ^e   Carducci, Michael A ^f   Chang, Sam S ^g   Choueiri, Toni K ^c   Hancock, Steven L ^h   Hudes, Gary R ⁱ   Jonasch, Eric ^j   Josephson, David ^k   Kuzel, Timothy M ^l   Levine, Ellis G ^m   Lin, Daniel W ⁿ   Margolin, Kim A ⁿ   Michaelson, M Dror ^o   Olencki, Thomas ^p   Pili, Roberto ^m   Ratliff, Thomas W ^q   Redman, Bruce G ^r   Robertson, Cary N ^s   Ryan, Charles J ^t   Sheinfeld, Joel ^a   Spiess, Philippe E ^u   Wang, Jue ^v   Wilder, Richard B ^u   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^d BARNES JEWISH HOSPITAL   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

^h STANFORD CANCER INSTITUTE   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m ROSWELL PARK CANCER INSTITUTE   (United States)

ⁿ SEATTLE CANCER CARE ALLIANCE   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^p OHIO STATE UNIVERSITY   (United States)

^q UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^r UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^s DUKE CANCER INSTITUTE   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^v NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

Clear cell tumors; Kidney disease; NCCN Clinical Practice Guidelines; NCCN Guidelines; Nephrectomy; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEMCITABINE; HEMOGLOBIN; INTERLEUKIN 2; LACTATE DEHYDROGENASE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ABDOMINAL PAIN; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CLEAR CELL CARCINOMA; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DIARRHEA; DISEASE SURVEILLANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HAIR COLOR; HAND FOOT SYNDROME; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERAMYLASEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INOPERABLE CANCER; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; KIDNEY FAILURE; KIDNEY SARCOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPHADENECTOMY; METASTASIS; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHRECTOMY; NEUTROPENIA; OBESITY; PAIN; PAPILLARY CARCINOMA; PATIENT SELECTION; PELVIS CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRACTICE GUIDELINE; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SIDE EFFECT; SMOKING HABIT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR VOLUME; VOMITING; WEAKNESS;

EID: 80052975816     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0082     Document Type: Review

References (83)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Karumanchi SA, Merchan J, Sukhatme VP. Renal cancer: molecular mechanisms and newer therapeutic options. Curr Opin Nephrol Hypertens 2002;11:37-42. (Pubitemid 34053336)
3. Choyke PL, Glenn GM, Walther MM, et al. Hereditary renal cancers. Radiology 2003;226:33-46. (Pubitemid 36163905)
4. DeVita VT Jr, Hellman S, Rosenberg SA. Cancer Principles and Practice of Oncology. 8th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
5. Horner MJ, Ries LA, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute. Available at: http://seer.cancer.gov/csr/ 1975-2006/. Accessed June 21, 2011.
6. Hricak H, Demas BE, Williams RD, et al. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. Radiology 1985;154:709-715. (Pubitemid 15162368)
7. Janus CL, Mendelson DS. Comparison of MRI and CT for study of renal and perirenal masses. Crit Rev Diagn Imaging 1991;32:69-118.
8. Blom JH, Van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 2009;55:28-34.
9. Blute ML, Leibovich BC, Cheville JC, et al. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol 2004;172:465-469. (Pubitemid 38900178)
10. Kuczyk M, Munch T, Machtens S, et al. The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience. BJU Int 2002;89:517-522. (Pubitemid 34948290)
11. Kuczyk M, Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 2005;48:252-257. (Pubitemid 40957099)
12. O'Malley RL, Godoy G, Kanofsky JA, Taneja SS. The necessity of adrenalectomy at the time of radical nephrectomy: a systematic review. J Urol 2009;181:2009-2017.
13. Hollingsworth JM, Miller DC, Dunn RL, et al. Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology. Urology 2006;67:1175-1180. (Pubitemid 43818097)
14. Leibovich BC, Blute ML, Cheville JC, et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 2004;171:1066-1070. (Pubitemid 38327528)
15. Shuch B, Lam JS, Belldegrun AS. Open partial nephrectomy for the treatment of renal cell carcinoma. Curr Urol Rep 2006;7:31-38. (Pubitemid 44624028)
16. Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw 2009;7:635-642; quiz 643.
17. Dash A, Vickers AJ, Schachter LR, et al. Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm. BJU Int 2006;97:939-945.
18. Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 2000;75:1236-1242.
19. Lee CT, Katz J, Shi W, et al. Surgical management of renal tumors 4 cm. or less in a contemporary cohort. J Urol 2000;163:730-736. (Pubitemid 30091605)
20. Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006;7:735-740. (Pubitemid 44283660)
21. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
22. Weight CJ, Lieser G, Larson BT, et al. Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol 2010;58:293-298.
23. Weight CJ, Larson BT, Gao T, et al. Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology 2010;76:631-637.
24. Funahashi Y, Hattori R, Yamamoto T, et al. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol 2009;55:209-215.
25. Rais-Bahrami S, Guzzo TJ, Jarrett TW, et al. Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int 2009;103:1355-1358.
26. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol 2009;182:1271-1279.
27. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer 2008;113:2671-2680.
28. Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21:3133-3140. (Pubitemid 46606295)
29. Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003;21:1214-1222. (Pubitemid 46606396)
30. Trump D, Elson P, Propert K, et al. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L IFN) in resected, high risk renal cell carcinoma (HR-RCC) [abstract]. Proc Am Soc Clin Oncol 1996;15:Abstract 648.
31. Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005;174:466-472; discussion 472; quiz 801.
32. Fossa SD, Kjolseth I, Lund G. Radiotherapy of metastases from renal cancer. Eur Urol 1982;8:340-342. (Pubitemid 13253332)
33. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-1076. (Pubitemid 38327529)
34. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655-1659. (Pubitemid 33126820)
35. Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966-970. (Pubitemid 32913522)
36. Polcari AJ, Gorbonos A, Milner JE, Flanigan RC. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol 2009;16:227-233.
37. Culp SH, Tannir NM, Abel EJ, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 2010;116:3378-3388.
38. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;98:2566-2575. (Pubitemid 37509519)
39. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-1188. (Pubitemid 15011332)
40. Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997;3:157-162.
41. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998;338:1272-1278. (Pubitemid 28216581)
42. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-696.
43. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-141. (Pubitemid 41702632)
44. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-3590.
45. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-3132. (Pubitemid 46606294)
46. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-296. (Pubitemid 34032623)
47. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97:1663-1671. (Pubitemid 36350710)
48. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124. (Pubitemid 46089672)
49. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
50. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-896. (Pubitemid 350002890)
51. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35. (Pubitemid 46630490)
52. Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757-763.
53. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-2111. (Pubitemid 350296300)
54. Rini BI, Choueiri TK, Elson P, et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008;113:1309-1314.
55. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-2143.
56. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
57. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281. (Pubitemid 46849157)
58. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-1861. (Pubitemid 40826133)
59. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-5480. (Pubitemid 41060823)
60. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-1694. (Pubitemid 41510145)
61. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972. (Pubitemid 46202316)
62. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109. (Pubitemid 39331023)
63. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280-1289.
64. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
65. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-4265.
66. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
67. Eisen T, Bukowski RM, Staehler M, et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 4524.
68. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 5023.
69. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-2524. (Pubitemid 43854967)
70. Dudek AZ, Zolnierek J, Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009;115:61-67.
71. Eichelberg C, Heuer R, Chun FK, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 2008;54:1373-1378.
72. Heuer R, Eichelberg C, Zacharias M, Heinzer H. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib [abstract]. Eur Urol Suppl 2009;8:183. Abstract 251.
73. Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients [abstract]. J Clin Oncol 2007;25:Abstract 5038.
74. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 2009;182:29-34; discussion 34.
75. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab [abstract]. J Clin Oncol 2008;26:Abstract 5123.
76. Zimmermann K, Schmittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76:350-354.
77. Dutcher JP, De Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202-209.
78. Gordon MS, Hussey M, Nagle RB, et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27:5788-5793.
79. Dutcher JP, Nanus D. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol, in press.
80. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545-1551. (Pubitemid 39318900)
81. Haas N, Manola J, Pins M, et al. ECOG 8802: phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features [abstract]. Presented at the ASCO Genitourinary Cancers Symposium 2009; February 26-28, 2009; Orlando, Florida. Abstract 285.
82. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003;98:962-969. (Pubitemid 37022096)
83. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621. (Pubitemid 38715767)